Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

NCT02226276 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Bone Metastases
HER2-positive Breast Cancer
Liver Metastases
Lung Metastases
Recurrent Breast Cancer
Soft Tissue Metastases
Stage IV Breast Cancer

Interventions

RADIATION: fludeoxyglucose F 18
PROCEDURE: positron emission tomography
PROCEDURE: computed tomography
BIOLOGICAL: trastuzumab
RADIATION: copper Cu 64-DOTA-trastuzumab
PROCEDURE: positron emission tomography
BIOLOGICAL: ado-trastuzumab emtansine
OTHER: laboratory biomarker analysis

Sponsor

City of Hope Medical Center

Collaborators

[object Object]